Toxicology — Acetaminophen Overdose

• Phase I metabolism and toxic metabolite formation: Acetaminophen undergoes hepatic metabolism primarily via glucuronidation (50–60%) and sulfation (20–30%), yielding inactive, water-soluble conjugates that are readily excreted. However, a minor pathway (~5–10% of normal doses, up to 20% of overdose doses) involves oxidation by cytochrome P450 2E1 (and to lesser extent 1A2 and 3A4) to form the highly reactive electrophilic metabolite N-acetyl-p-benzoquinone imine (NAPQI). This unstable intermediate is normally rapidly inactivated by conjugation with reduced glutathione, catalyzed by glutathione-S-transferases, producing mercapturic acid conjugates that are excreted in the urine. In overdose settings, this protective mechanism becomes rate-limiting.

• Glutathione depletion and critical threshold concept: In therapeutic doses, hepatic glutathione stores remain intact. However, at plasma concentrations exceeding the nomogram threshold (defined as >200 μg/mL at 4 hours post-ingestion, with lower thresholds at later times), NAPQI is formed faster than it can be inactivated by the available glutathione pool. Hepatic GSH becomes depleted to less than 30% of baseline within 8–12 hours, eliminating the cell's primary defense against electrophilic stress. Once GSH is depleted, excess NAPQI accumulates and covalently binds to critical nucleophilic sites on hepatic proteins, including those in the mitochondrial membrane and oxidative stress response proteins. The critical threshold for GSH depletion is reached when cumulative acetaminophen exposure exceeds ~150 mg/kg in a 70-kg adult (approximately 10.5 g total), though this varies based on individual factors (see Risk Factors).

• Mitochondrial injury, oxidative stress, and hepatocyte death: NAPQI-protein adducts damage the mitochondrial electron transport chain, leading to loss of ATP production and mitochondrial permeability transition. The resulting collapse of the mitochondrial membrane potential triggers massive oxidative stress through uncoupling of oxidative phosphorylation and increased superoxide formation. The hepatocyte becomes unable to maintain ATP-dependent homeostasis, leading to oncotic necrosis (in the initial 24–72 hours) rather than apoptosis, characterized by cell swelling, membrane rupture, and release of cellular contents. Simultaneously, reactive oxygen species (ROS) directly damage lipid membranes through peroxidation and activate pro-inflammatory signaling (via JNK, c-Jun N-terminal kinase, especially in the pericentral hepatocytes around the central vein where CYP2E1 is most abundant). This creates a feed-forward cycle of oxidative damage, triggering additional mitochondrial dysfunction and hepatocyte death. The pattern of injury is predominantly centrilobular (zone 3) necrosis, correlating with the highest expression of CYP2E1 in this zone.

• Inflammatory amplification and systemic effects: As hepatocytes undergo necrosis, damage-associated molecular patterns (DAMPs) are released, activating innate immunity through TLR9 and other pattern recognition receptors. Neutrophil infiltration and release of additional ROS amplify hepatic injury. In severe cases, loss of hepatocyte mass exceeds the liver's regenerative capacity (which typically supports recovery if the patient survives the acute phase), leading to acute liver failure with jaundice, coagulopathy (prolonged PT/INR), hepatic encephalopathy, and eventual multi-organ failure. The kidneys can also suffer direct NAPQI-mediated toxicity, producing acute kidney injury through similar mechanisms of mitochondrial dysfunction in proximal tubule cells.

• Acute overdose with suicidal intent: Deliberate ingestion of large quantities (typically >15 g or >200 mg/kg) in a single exposure represents the classic presentation. These patients often present with known acute ingestion, allowing calculation of the dose and use of the Rumack-Matthew nomogram to guide treatment. The mechanism is straightforward overwhelming of glucuronidation and sulfation capacity with shunting to the CYP450 pathway.

• Unintentional overdose through therapeutic duplication: This increasingly common scenario occurs when patients unknowingly exceed safe daily limits (typically 3–4 g/day for adults, 2 g/day for those at high risk) by combining multiple over-the-counter and prescription products containing acetaminophen (e.g., combination cold medications, pain relievers, and prescription opioid-acetaminophen combinations). Chronic overuse over days to weeks can cause toxicity at lower total doses than acute ingestion because baseline hepatic glutathione stores become chronically depleted. These patients present diagnostic and prognostic challenges because they often lack awareness of overdose and the onset is insidious.

• Chronic alcohol use: Alcohol consumption upregulates CYP2E1 and depletes hepatic glutathione stores through increased basal oxidative stress and impaired GSH synthesis (alcohol inhibits cysteine uptake). Chronic alcoholics show hepatotoxicity at doses as low as 2–3 g/day or total doses of 6–10 g; this represents perhaps the single most important risk factor in clinical practice. Additionally, alcoholic liver disease itself reduces hepatic metabolic capacity and regenerative ability.

• Fasting and malnutrition: Reduced caloric intake impairs hepatic glutathione synthesis and increases reliance on the CYP450 pathway. Patients with poor nutritional status show enhanced susceptibility to acetaminophen toxicity.

• Hepatic disease (pre-existing cirrhosis, viral hepatitis, fatty liver disease): Cirrhotic patients have diminished hepatic synthetic function, reduced GSH stores, and impaired regenerative capacity. They require lower doses to manifest toxicity. However, interestingly, patients with acute viral hepatitis may have paradoxically lower risk due to lower CYP2E1 expression during acute inflammation.

• Genetic polymorphisms in drug metabolism: Variations in CYP2E1, glutathione-S-transferase (GST), and N-acetyltransferase (NAT2) genes influence individual susceptibility. Slow acetylators (NAT2) may be at higher risk; however, the clinical impact is modest compared to environmental factors.

• Age extremes: Neonates and young infants have reduced glucuronidation capacity and are particularly vulnerable. Elderly patients, especially those on multiple medications with hepatic metabolism and those with age-related decline in liver function, show increased susceptibility.

• Medications inducing CYP2E1: Chronic use of isoniazid, rifampin, and chronic alcohol increases acetaminophen toxicity risk through enhanced NAPQI production.

• Glutathione-depleting conditions: Conditions causing systemic GSH depletion (HIV infection, severe sepsis, malignancy) increase risk.

• Phase 1 (0–24 hours, the "honeymoon period"): Patients typically present with nonspecific symptoms that may be mild or absent, leading to dangerous underestimation of severity. Nausea, vomiting, anorexia, and abdominal pain (particularly right upper quadrant discomfort) are common. Diaphoresis and malaise may occur. Notably, the absence of symptoms does not exclude serious toxicity—some patients ingest massive doses and feel entirely well during this phase. This period represents the window of opportunity for treatment; liver enzymes and INR remain normal or near-normal because hepatocyte necrosis has not yet begun to cause measurable synthetic dysfunction.

• Phase 2 (24–72 hours, apparent recovery): A deceptively dangerous period occurs when initial symptoms abate and patients may feel improved, leading them or caregivers to falsely believe recovery is occurring. However, hepatotoxicity is actively developing during this window. Transaminases (ALT and AST) begin to rise sharply, often reaching peak values >1,000 IU/L or much higher. Right upper quadrant tenderness becomes more apparent. The patient may begin experiencing right-sided abdominal pain due to hepatic swelling and inflammation. Prothrombin time (PT/INR) may begin to prolong. Some patients develop diarrhea. This phase is often missed clinically because the patient feels "better" and presents to evaluation late.

• Phase 3 (72–96 hours onward, hepatic failure): This phase marks the onset of hepatic dysfunction. Jaundice becomes clinically apparent (bilirubin typically rises >3 mg/dL). Hepatic encephalopathy emerges, initially manifested by subtle personality changes, confusion, or reversal of sleep-wake cycle, progressing to asterixis (flapping tremor), somnolence, and ultimately coma (grades I–IV). Coagulopathy reflects loss of synthetic function, with INR >1.5 indicating significant hepatocyte death. Hypoglycemia develops as hepatic glucose production fails. Hyperbilirubinemia progresses, along with elevated aminotransferases (though these may begin to decline as hepatocytes are destroyed and fewer remain to release enzymes—a paradoxical decline in ALT/AST despite worsening liver function). Renal failure may develop (usually secondary to hepatorenal syndrome but direct tubular injury can occur). Metabolic acidosis, particularly with elevated anion gap (due to lactate accumulation from mitochondrial dysfunction), signals severe hepatic impairment. Cardiovascular collapse, disseminated intravascular coagulation (DIC), cerebral edema, and multi-organ failure follow in the most severe cases.

• Hepatomegaly: On examination, the liver may be enlarged and tender, particularly over the right upper quadrant, due to inflammation and hepatic swelling.

• Pallor and diaphoresis: Systemic manifestations of hepatotoxicity and sympathetic activation.

• Important clinical variant—chronic acetaminophen toxicity: Patients ingesting supratherapeutic doses over days to weeks (often unknowingly through combination products) present with a more indolent course. They may present with nonspecific symptoms (malaise, anorexia, fatigue) and laboratory evidence of hepatotoxicity without the dramatic rise in transaminases seen in acute overdose. The clinical picture resembles viral hepatitis or drug-induced liver injury more than classic acute overdose. These patients can progress to acute liver failure if exposure continues.

• Serum acetaminophen concentration and the Rumack-Matthew nomogram: This is the gold standard for risk stratification in acute overdose (single ingestion with known or estimated time of ingestion). A serum level should be drawn at least 4 hours post-ingestion (earlier levels are unreliable because the drug may still be in the absorption/distribution phase). The Rumack-Matthew nomogram provides a line on a semi-log graph relating plasma acetaminophen concentration (y-axis, log scale) to hours post-ingestion (x-axis, linear scale). Two critical reference lines are:
• Higher risk line (20% risk of hepatotoxicity): Used for patients with risk factors (chronic alcohol use, fasting, hepatic disease, medications inducing CYP450)
• Standard risk line (5% risk of hepatotoxicity): Used for otherwise healthy patients

• Liver function tests and hepatic synthetic function markers:
• ALT/AST: Markedly elevated in acute overdose (often >1,000 IU/L), reflecting hepatocyte necrosis. Peak levels typically occur 48–72 hours post-ingestion. ALT is more specific for liver injury. The degree of elevation does not always correlate with prognosis; severe hepatic failure can occur even with "modest" transaminase elevation if substantial hepatocyte death has occurred. Importantly, during Phase 1 (initial 24 hours), transaminases may be normal or only mildly elevated.
• INR/PT: The most important indicator of synthetic function. INR is more sensitive than bilirubin or encephalopathy for assessing prognosis. An INR >1.5 at 24 hours or any INR >4 indicates high mortality risk without transplantation. The PT/INR begins to lengthen during Phase 2–3.
• Bilirubin: Rises later (Phase 3), typically after transaminases peak. Indicates cholestasis or hepatocyte necrosis.
• Albumin: May be low in chronic cases (reflects chronic synthetic dysfunction) but remains normal early in acute overdose because of the liver's large reserve for albumin synthesis.

• Metabolic parameters and markers of severity:
• Arterial blood gas: Metabolic acidosis with anion gap elevation (lactate accumulation) indicates mitochondrial dysfunction and severe hepatic impairment; this is a poor prognostic sign.
• Glucose: Hypoglycemia indicates loss of hepatic synthetic and metabolic function.
• Creatinine and BUN: Assess renal function; elevation may indicate hepatorenal syndrome or direct acetaminophen nephrotoxicity.
• Phosphate: Hyperphosphatemia can occur; very low phosphate is an ominous sign in fulminant failure.

• King's College Hospital Criteria (for fulminant hepatic failure prognosis): These criteria help identify patients requiring urgent liver transplantation:
• For acetaminophen-induced fulminant failure: INR >6.5 OR any three of: age >40 years, time from ingestion to jaundice >7 days, bilirubin >300 μmol/L (17.5 mg/dL), creatinine >300 μmol/L (3.4 mg/dL), or severe encephalopathy (grade III–IV).
• Meeting criteria indicates >80% mortality without transplantation and warrants immediate referral to a transplant center.

• Prothrombin time/INR trends: The trend in INR is often more informative than a single value. Worsening (rising) INR despite NAC treatment indicates progressive hepatic failure. An INR that improves or stabilizes after NAC suggests the patient may recover without transplantation.

• Imaging findings:
• Abdominal ultrasound or CT: Hepatomegaly, loss of normal echogenicity (with diffuse edema), and ascites may be seen in severe cases. These findings are nonspecific and mainly serve to exclude other acute abdominal pathology and assess for complications (bleeding, perforation). Imaging is not required for diagnosis but may be obtained if clinical presentation is atypical or alternative diagnoses are considered.

• Differential diagnosis considerations: The constellation of acute hepatitis with marked transaminase elevation should prompt consideration of:
• Viral hepatitis (A, B, C, E): Negative serologies and absence of prodromal illness favor acetaminophen
• Acute alcoholic hepatitis: History of heavy alcohol use; may be concurrent

Immediate stabilisation

• ABCs and glucose: check a fingerstick immediately — hypoglycemia from failed hepatic gluconeogenesis is a rapidly reversible cause of altered mental status. Screen for co-ingestants (salicylate level, ECG for QRS/QTc, opioid or anticholinergic effects from combination products).
• Gastrointestinal decontamination: activated charcoal (single dose, ~1 g/kg) benefits patients presenting early after a large ingestion with an intact or protected airway; the AACT/EAPCCT position statement supports charcoal in the first hour, with extension to a few hours after massive or modified-release ingestion. It must never delay N-acetylcysteine. Syrup of ipecac and routine gastric lavage are obsolete and contraindicated.

First-line therapy — antidote (glutathione repletion)

• N-acetylcysteine (NAC): a cysteine prodrug that replenishes hepatic glutathione, serves as a direct NAPQI-conjugating substrate, expands sulfation capacity, and — in late presenters — improves microvascular oxygen delivery and has anti-inflammatory effects. Efficacy is near-complete when begun within 8 hours of ingestion, so start NAC empirically without waiting for the level when presentation is late, the ingestion time is unknown, or the ingestion is staggered.
• IV (Acetadote) 21-hour regimen: 150 mg/kg loading dose, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours. Preferred in vomiting, GI bleeding, hepatic failure, and pregnancy (fetal glutathione depletion is the concern).
• Oral regimen: 140 mg/kg load, then 70 mg/kg every 4 hours for 17 doses.
• Treatment is extended beyond the standard course if acetaminophen remains detectable or transaminases and INR are still worsening.

Escalation

• Hemodialysis: reserved for massive ingestion with extreme levels, coma, or refractory lactic acidosis; the EXTRIP workgroup endorses dialysis in this narrow setting (acetaminophen is small and minimally protein-bound), with the NAC infusion rate increased during the run.
• Fomepizole (CYP2E1 inhibition) is adjunctive and investigational, not guideline-standard.

Definitive management

• Transplant referral: per AASLD acute liver failure guidance, transfer early to a transplant center for encephalopathy, rising INR, acidosis, or King's College criteria. Orthotopic liver transplantation is definitive.
• Avoid: empiric fresh frozen plasma without bleeding or a planned procedure (it obscures INR trend, the key prognostic marker), plus all further hepatotoxins and sedatives.

Complications of the poisoning

• Fulminant hepatic failure: loss of hepatocyte mass beyond regenerative capacity. Signalled by encephalopathy plus rising INR — coagulopathy with encephalopathy defines acute liver failure. Emergency: immediate transplant-center transfer per AASLD.
• Cerebral edema and intracranial hypertension: the leading cause of death in hyperacute liver failure; ammonia and glutamine-driven astrocyte swelling with loss of autoregulation. Signalled by grade III–IV encephalopathy, hypertension with bradycardia, pupillary changes, or posturing. Emergency — head-of-bed elevation, hyperosmolar therapy, and airway protection.
• Hypoglycemia: failed gluconeogenesis and glycogenolysis; signalled by altered mental status with a low fingerstick. Check glucose repeatedly; requires dextrose infusion.
• Coagulopathy and bleeding: failure of factor synthesis (factor VII first, shortest half-life) — rising INR is both the marker and the prognostic index. Correct only for active bleeding or procedures.
• Acute kidney injury: direct NAPQI-mediated proximal tubular injury (can occur even with modest hepatotoxicity) plus later hepatorenal physiology; signalled by rising creatinine and oliguria. Predicts poor outcome and appears in King's College criteria.
• Anion-gap lactic acidosis: mitochondrial dysfunction plus impaired hepatic lactate clearance; early acidosis after massive ingestion is an ominous sign and a dialysis trigger.
• Sepsis and SIRS: impaired hepatic Kupffer-cell clearance and immunoparesis; fever may be absent, so a low threshold for cultures is required.
• Other: ARDS, pancreatitis, and multi-organ failure in advanced disease.

Complications of treatment

• Anaphylactoid reaction to IV NAC: a direct, dose-related histamine release — not IgE-mediated. Occurs during the loading infusion as flushing, urticaria, bronchospasm, or hypotension. Management is to pause the infusion, give an antihistamine (diphenhydramine), treat bronchospasm, and restart NAC at a slower rate — it is not a permanent contraindication. Severe bronchospasm or hypotension is an emergency.
• Hyponatremia/fluid overload: from the large free-water volume of dilute NAC, chiefly in small children — weight-based fluid volumes prevent it.
• Vomiting with oral NAC: risks aspiration; use antiemetics or switch to IV.
• Activated charcoal aspiration: charcoal pneumonitis in obtunded patients without a protected airway.

• The single best next step in a late or unclear presentation is to start N-acetylcysteine, not to wait for the level. If the ingestion time is unknown, the ingestion was staggered/chronic, or presentation is beyond 8 hours, empiric NAC is correct; the Rumack-Matthew nomogram applies only to a single acute ingestion with a known time.
• Draw the level no earlier than 4 hours post-ingestion. A pre-4-hour level is uninterpretable because absorption and distribution are incomplete — a "reassuring" 2-hour level is the classic trap.
• A well-appearing patient with normal LFTs proves nothing. Phase 1 is the honeymoon period; the stem describing an asymptomatic teenager with normal transaminases hours after ingesting a bottle of pills is still a treat-now scenario.
• INR is the prognostic vital sign, not ALT. Transaminases in the thousands with a normal INR is survivable; a falling ALT with a rising INR and bilirubin means hepatocytes are gone, not recovering.
• Classic association tested: centrilobular (zone 3) necrosis from CYP2E1-rich pericentral hepatocytes, and the potentiating effect of chronic alcohol and isoniazid (CYP2E1 induction plus glutathione depletion), so toxicity occurs at surprisingly modest doses.
• AST/ALT well above 1,000 IU/L points to acetaminophen (or ischemic hepatitis/shock liver), not alcoholic hepatitis — the common distractor. Alcoholic hepatitis gives AST:ALT >2:1 with values usually under a few hundred.
• Flushing, urticaria, or wheeze during the NAC loading infusion is an anaphylactoid (histamine-release) reaction, not a true allergy. Slow the infusion and give an antihistamine; "permanently discontinue NAC" is always the wrong answer.
• Don't reflexively correct the INR with FFP. AASLD advises against it absent bleeding or a procedure, because the INR trend guides transplant listing — and King's College criteria (arterial pH, or the triad of INR, creatinine, and grade III–IV encephalopathy) are the trigger for transplant referral.